BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 17003775)

  • 1. Prostate-specific antigen adjusted for total prostatic tumor volume as a predictor for outcome after radical prostatectomy.
    Hayashi N; Urashima M; Ikemoto I; Kuruma H; Arai Y; Kuwao S; Baba S; Egawa S
    Prostate Cancer Prostatic Dis; 2007; 10(1):60-5. PubMed ID: 17003775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visual estimation of the tumor volume in prostate cancer: a useful means for predicting biochemical-free survival after radical prostatectomy?
    May M; Siegsmund M; Hammermann F; Loy V; Gunia S
    Prostate Cancer Prostatic Dis; 2007; 10(1):66-71. PubMed ID: 17189956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
    Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
    J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
    Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results.
    Roehl KA; Eggener SE; Loeb S; Smith ND; Antenor JA; Catalona WJ
    Urol Oncol; 2006; 24(6):465-71. PubMed ID: 17138126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relative importance of anatomic and PSA factors to outcomes after radical prostatectomy for prostate cancer.
    Vollmer RT; Humphrey PA
    Am J Clin Pathol; 2001 Dec; 116(6):864-70. PubMed ID: 11764075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The maximum tumour length in biopsy cores as a predictor of outcome after radical prostatectomy.
    Hayashi N; Urashima M; Kuruma H; Arai Y; Kuwao S; Iwamura M; Egawa S
    BJU Int; 2008 Jan; 101(2):175-80. PubMed ID: 17850362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of p53 and X-ray repair cross-complementing group 1 polymorphisms on prostate-specific antigen recurrence in prostate cancer post radical prostatectomy.
    Huang SP; Huang CY; Wang JS; Liu CC; Pu YS; Yu HJ; Yu CC; Wu TT; Huang CH; Wu WJ; Chou YH; Wu MT
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6632-8. PubMed ID: 18006764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database.
    Freedland SJ; Hotaling JM; Fitzsimons NJ; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL
    Eur Urol; 2008 Apr; 53(4):758-64; discussion 765-6. PubMed ID: 17868976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era.
    Boorjian SA; Thompson RH; Siddiqui S; Bagniewski S; Bergstralh EJ; Karnes RJ; Frank I; Blute ML
    J Urol; 2007 Sep; 178(3 Pt 1):864-70; discussion 870-1. PubMed ID: 17631342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
    Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
    J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.
    Chung CS; Chen MH; Cullen J; McLeod D; Carroll P; D'Amico AV
    Urology; 2008 Jan; 71(1):136-40. PubMed ID: 18242382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy.
    Yamamoto S; Yonese J; Kawakami S; Ohkubo Y; Tatokoro M; Komai Y; Takeshita H; Ishikawa Y; Fukui I
    Eur Urol; 2007 Sep; 52(3):696-701. PubMed ID: 17412490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
    Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive-block ratio in radical prostatectomy specimens is an independent predictor of prostate-specific antigen recurrence.
    Marks RA; Lin H; Koch MO; Cheng L
    Am J Surg Pathol; 2007 Jun; 31(6):877-81. PubMed ID: 17527074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour length of the largest focus predicts prostate-specific antigen-based recurrence after radical prostatectomy in clinically localized prostate cancer.
    Mizuno R; Nakashima J; Mukai M; Okita H; Kosugi M; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Oya M
    BJU Int; 2009 Nov; 104(9):1215-8. PubMed ID: 19389009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens.
    Marks RA; Koch MO; Lopez-Beltran A; Montironi R; Juliar BE; Cheng L
    Hum Pathol; 2007 Aug; 38(8):1207-11. PubMed ID: 17490720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
    Khatami A; Hugosson J; Wang W; Damber JE
    Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.